Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours

Informations projet

Tumor-Treg-Targeting

N° de convention de subvention: 765394

DOI

10.3030/765394

Projet clôturé

Date de signature de la CE 2 Août 2017

Date de début 1 Juin 2018

Date de fin 30 Novembre 2022

Financé au titre de

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coût total

€ 1 273 933,58

Contribution de l’UE

€ 1 273 933,58

Coordonné par

UNIVERSIDAD DE NAVARRA
Spain

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Documents, reports (2)

ESR research outputs (publications, patent applications and presentations at conferences) and products)

Report that will compile relevant information concerning the research outputs publications done patent applications obtained presentations carried out at conferences and products achieved by each ESR

Dissemination of Tumor Treg Taregting results and achievements to the Scientific Community and products

This report will compile all the actions urdertaken by project partners to disseminate at national and international levels the project results and achievements to the Scientific Community and Wider Public

Other (3)

Completion of PhD Thesis and award of Doctoral Degrees

Completion of PhD Thesis and award of Doctoral Degrees: 5 PhD Thesis are expected. After thirty-six months each ESR will submitt his/her thesis which will be evaluated by the supervisors, the local GSC, and an external reviewer. The thesis is then defended in an oral examination (viva voce).

ESR organised workshop on antibody mediated tumour therapy

During the last network meeting (month 45 in Utrecht/NL) ESR-organized School on antibody-based tumour therapy will be held. This international meeting (3-5 days) will be organized by the ESRs. This meeting will be open to a general, interested public and other scientists outside of the network. This conference will include invited international speakers chosen and invited by the ESRs. Speakers and poster presentations will further be selected from abstracts, submitted by participants. Thus this meeting will allow the network to report their findings and advances to the scientific community, and ESRs to further plan their scientific careers. To fully organize such a School will allow the students to be further trained in organizing conferences, attracting funding/sponsoring from companies and in networking with world-leading scientists. It is the intention that such a School will be continued even after the completion of this project, fostering European networking in this area.

"4-day business course (""learning by simulation"")"

A 4-day business course (biologicals simulation course) will be developed to train Ph.D. level scientists in biopharmaceutical drug discovery and development, available through LBS (www.learningbysimulation.com). LBS will specifically set up one of their courses for the 5 ESRs of this training network.

Websites, patent fillings, videos etc. (1)

Launch and management of the Tumor Treg Targerting website

General audience will be reached via the establishment of a project specific web-site. The web-site will make reference to the aims, the background of the project, and general as well as specific advances in the field of cancer therapy. Specific breakthrough achievements of the ESR's projects will be posted, which will regularly be updated with PDFs of publications, made available by 6 months post publication or earlier. Any press article and review articles will be available for download or upon request. ESRs will use the website to disseminate their projects. They will place short videos explaining in easily understable, non specialist language, their projects and further implications for the wider society. In addition, the web-site will be used to advertise the job offers during the recruitment period. The website will also contain special area for social media with the information that will appear on the project twitter, facebook, linkedin and Youtube.

Publications

Peer reviewed articles (18)

Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice

Auteurs: Ardaiz N, Gomar C, Vasquez M, Tenesaca S, Fernandez-Sendin M, Di Trani CA, Belsué V, Escalada J, Werner U, Tennagels N, Berraondo P.
Publié dans: Front Pharmacol., 2021, ISSN 1663-9812
Éditeur: Frontiers Media S.A.
DOI: 10.3389/fphar.2020.591293

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

Auteurs: Bella Á, Arrizabalaga L, Di Trani CA, Cirella A, Fernandez-Sendin M, Gomar C, Russo-Cabrera JS, Rodríguez I, González-Gomariz J, Alvarez M, Teijeira Á, Medina-Echeverz J, Hinterberger M, Hochrein H, Melero I, Berraondo P, Aranda F.
Publié dans: Oncoimmunology, 2022, ISSN 2162-4011
Éditeur: Landes Bioscience
DOI: 10.1080/2162402x.2022.2098657

Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.

Auteurs: Huang, Shuyu; van Duijnhoven, Sander M J; Sijts, Alice J A M; van Elsas, Andrea; Immunologie; dI&I RA-I&I I&I
Publié dans: Journal of Cancer Research and Clinical Oncology, Numéro 5, 2020, ISSN 0171-5216
Éditeur: Springer Verlag
DOI: 10.1007/s00432-020-03404-6

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

Auteurs: Teijeira A, Migueliz I, Garasa S, Karanikas V, Luri C, Cirella A, Olivera I, Cañamero M, Alvarez M, Ochoa MC, Rouzaut A, Rodriguez-Ruiz ME, Sanmamed MF, Klein C, Umaña P, Ponz M, Bacac M, Melero I.
Publié dans: Theranostics, 2022, ISSN 1838-7640
Éditeur: Ivyspring International Publisher
DOI: 10.7150/thno.63359

Isotype selection for antibody‐based cancer therapy

Auteurs: N. Vukovic, A. Elsas, J. S. Verbeek, D. M. W. Zaiss
Publié dans: Clinical & Experimental Immunology, Numéro 203/3, 2021, Page(s) 351-365, ISSN 0009-9104
Éditeur: Blackwell Publishing Inc.
DOI: 10.1111/cei.13545

INTERLEUKIN-12 MESSAGE IN A BOTTLE

Auteurs: Cirella, A. Berraondo, P. Di-Trani, C.A. Melero, I.
Publié dans: Clin Cancer Res, 2020, ISSN 1078-0432
Éditeur: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-20-3250

Mouse IgG2a Isotype Therapeutic Antibodies Elicit Superior Tumor Growth Control Compared with mIgG1 or mIgE

Auteurs: Vukovic N, Segués A, Huang S, Waterfall M, Sijts AJAM, Zaiss DM.
Publié dans: Cancer Res Commun, 2023, ISSN 2767-9764
Éditeur: American Association for Cancer Research
DOI: 10.1158/2767-9764.crc-22-0356

Novel strategies exploiting interleukin-12 in cancer immunotherapy

Auteurs: Cirella A, Luri-Rey C, Di Trani CA, Teijeira A, Olivera I, Bolaños E, Castañón E, Palencia B, Brocco D, Fernández-Sendin M, Aranda F, Berraondo P, Melero I. Novel strategies exploiting interleukin-12 in cancer immunotherapy
Publié dans: Pharmacology & Therapeutics, 2022, ISSN 0163-7258
Éditeur: Pergamon Press
DOI: 10.1016/j.pharmthera.2022.108189

Advances in mRNA-based drug discovery in cancer immunotherapy.

Auteurs: Di Trani CA, Fernandez-Sendin M, Cirella A, Segués A, Olivera I, Bolaños E, Melero I, Berraondo P.
Publié dans: Expert Opin Drug Discov., 2022, ISSN 1746-0441
Éditeur: Informa Healthcare
DOI: 10.1080/17460441.2021.1978972

A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing

Auteurs: Shuyu Huang, Aina Segués, David Lutje Hulsik, Dietmar M. Zaiss, Alice J.A.M. Sijts, Sander M.J. van Duijnhoven, Andrea van Elsas
Publié dans: Journal of Immunological Methods, Numéro 483, 2020, Page(s) 112811, ISSN 0022-1759
Éditeur: Elsevier BV
DOI: 10.1016/j.jim.2020.112811

Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications

Auteurs: Angela Bella; Claudia Augusta Di Trani; Myriam Fernandez-Sendin; Leire Arrizabalaga; Assunta Cirella; Alvaro Teijeira; José Medina-Echeverz; Ignacio Melero; Pedro Berraondo; Fernando Aranda
Publié dans: Cancers, Numéro 3, 2021, ISSN 2072-6694
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers13050963

Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors

Auteurs: Shirley Tenesaca; Marcos Vasquez; Maite Alvarez; Itziar Otano; Myriam Fernandez-Sendin; Claudia Augusta Di Trani; Nuria Ardaiz; Celia Gomar; Angela Bella; Fernando Aranda; José Medina-Echeverz; Ignacio Melero; Pedro Berraondo
Publié dans: Journal for Immunotherapy of Cancer, Numéro 1, 2021, ISSN 2051-1426
Éditeur: BMJ publishing group
DOI: 10.1136/jitc-2020-001587

Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity

Auteurs: Fernandez-Sendin M, Di Trani CA, Bella A, Vasquez M, Ardaiz N, Gomar C, Arrizabalaga L, Ciordia S, Corrales FJ, Aranda F, Berraondo P.
Publié dans: Frontiers in immunology, 2021, ISSN 1664-3224
Éditeur: Lausanne: Frontiers Media S.A., 2010-
DOI: 10.3389/fimmu.2020.620283

Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils

Auteurs: Teijeira A, Garasa S, Ochoa MDC, Cirella A, Olivera I, Glez-Vaz J, Andueza MP, Migueliz I, Alvarez M, Rodríguez-Ruiz ME, Rouzaut A, Berraondo P, Sanmamed MF, Perez Gracia JL, Melero I
Publié dans: Eur J Immunol, 2021, ISSN 0014-2980
Éditeur: John Wiley & Sons Ltd.
DOI: 10.1002/eji.202049029

Purification of murine immunoglobulin E (IgE) by thiophilic interaction chromatography (TIC)

Auteurs: Natasa Vukovic, Salim Harraou, Sander M.J. van Duijnhoven, Dietmar M. Zaiss, Andrea van Elsas
Publié dans: Journal of Immunological Methods, Numéro 489, 2021, Page(s) 112914, ISSN 0022-1759
Éditeur: Elsevier BV
DOI: 10.1016/j.jim.2020.112914

A Human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes

Auteurs: Vukovic, Natasa; Halabi, Samer; Russo-Cabrera, Joan Salvador; Blokhuis, Bart; Berraondo, Pedro; Redegeld, Frank A M; Zaiss, Dietmar M W; Afd Pharmacology; LS Immunologie; Pharmacology
Publié dans: VOLUME=298;ISSUE=8;STARTPAGE=1;ISSN=0021-9258;TITLE=Journal of Biological Chemistry, Numéro 7, 2022, ISSN 0021-9258
Éditeur: American Society for Biochemistry and Molecular Biology Inc.
DOI: 10.1016/j.jbc.2022.102153

Shortened hinge design of Fab x sdAb-Fc bispecific antibodies enhances redirected T-Cell killing of tumor cells

Auteurs: Shuyu Huang; Aina Segués; Martin Waterfall; David Wright; Charlotte Vayssiere; Sander M. J. van Duijnhoven; Andrea van Elsas; Alice J. A. M. Sijts; Dietmar M. Zaiss
Publié dans: Biomolecules; Volume 12; Numéro 10; Pages: 1331, Numéro 1, 2020, ISSN 0171-5216
Éditeur: Springer Verlag
DOI: 10.3390/biom12101331

Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies

Auteurs: Aina Segués, Sander M.J. van Duijnhoven, Marc Parade, Lilian Driessen, Nataša Vukovic, Dietmar Zaiss, Alice J.A.M. Sijts, Pedro Berraondo, Andrea van Elsas
Publié dans: Journal of Immunological Methods, Numéro 499, 2021, Page(s) 113173, ISSN 0022-1759
Éditeur: Elsevier BV
DOI: 10.1016/j.jim.2021.113173

Book chapters (1)

Opportunities and challenges of bi-specific antibodies

Auteurs: Segués A, Huang S, Sijts A, Berraondo P, Zaiss DM
Publié dans: Int Rev Cell Mol Biol, 2022, ISSN 1937-6448
Éditeur: Elsevier Inc.
DOI: 10.1016/bs.ircmb.2022.05.001